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Abstract 
Objective 
To assess the prevalence and moderators of low bone mass, osteopenia and osteoporosis in 
schizophrenia patients. 
Method 
Major electronic databases were searched from inception till 12/2013 for studies reporting the 
prevalence of low bone mass (osteopenia + osteoporosis = primary outcome), osteopenia or 
osteoporosis in schizophrenia patients.  Two independent authors completed methodological 
appraisal and extracted data.  A random effects meta-analysis was utilised.   
Results 
Nineteen studies were included (n=3,038 with schizophrenia; 59.2% male; age 24.5-58.9 years). The 
overall prevalence of low bone mass was 51.7% (95% CI=43.1-60.3%); 40.0% (CI=34.7-45.4%) had 
osteopenia and 13.2% (CI=7.8-21.6%) had osteoporosis. Compared with controls, schizophrenia 
patients had significantly increased risk of low bone mass (OR=1.9, CI=1.30-2.77, p<0.001, n=1,872) 
and osteoporosis (OR=2.86, CI=1.27-6.42, p=0.01, n=1,824), but not osteopenia (OR=1.33, CI=0.934-
1.90, p=0.1, n=1,862). In an exploratory regression analysis, older age (p=0.004) moderated low 
bone mass, whilst older age (p<0.0001) and male sex (p<0.0001) moderated osteoporosis.  The 
subgroup analyses demonstrated high heterogeneity, but low bone mass was less prevalent in North 
America (35.5%, CI=26.6-45.2%) than Europe (53.6%, CI=38.0-68.5%) and Asia (58.4%, CI=48.4-
67.7%), and in mixed in-/outpatients (32.9%, CI=49.6-70.1%) versus inpatients (60.3%, CI=49.6-
70.1%).   
Conclusion 
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Reduced bone mass (especially osteoporosis) is significantly more common in people with 
schizophrenia than controls.   
Summations 
• Low bone mass affects more than half of patients with schizophrenia and is approximately 
twice as common compared to age- and sex-matched controls.   
• Osteoporosis is over two and a half times more common in patients than in controls.   
• Multidisciplinary teams should routinely screen and implement appropriate interventions 
targeting bone health.    
Considerations 
• There was a paucity and inconsistency in the reporting of factors that may influence the 
prevalence of low bone mass across studies. 
• All of the studies included were cross-sectional; therefore directionality of the association 
between the variables investigated and the observed low bone mass cannot be deduced 
with certainty. 
• We could not clearly elucidate the influence of antipsychotics since there were inadequate 
data on specific medications.  
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Introduction 
Osteoporosis is a progressive systemic skeletal disease characterised by low bone mass and 
microarchitectural deterioration of bone tissue resulting in a profound increased fracture risk (1, 2).  
Osteoporosis is a global public health concern, affecting more than 200 million people worldwide (3) 
and the associated fractures are related with increased morbidity and mortality (2, 4).  Awareness of 
the elevated risk of osteoporosis, osteopenia, which is a precursor to osteoporosis but not a disease 
category in its own right, and low bone mass in schizophrenia is increasing (5, 6). However, research 
investigating bone health lags behind progress in other medical areas, such as obesity and metabolic 
syndrome (7, 8).  Schizophrenia patients are thought to be at risk of low bone mass (including 
osteoporosis and osteopenia) due to antipsychotic-induced hyperprolactinemia (6, 7, 9, 10) and a 
plethora of lifestyle influences, including physical inactivity (5, 8). In non-mental health settings, 
common risk factors increasing a person’s propensity for osteoporosis include smoking (11), physical 
inactivity, polydipsia, alcoholism, alcohol misuse, hypogonadism, a family or personal history of 
fractures and vitamin D deficiency (3, 4). Smoking (12), physical inactivity (13, 14) and vitamin D 
deficiency (15) are all increased in schizophrenia patients and when coupled with the increased 
threat of hyperprolactinaemia (16), the risk of low bone mass is in this population is considerable.  
These factors may explain why two recent, large population-cohort studies (17, 18) found that 
people with schizophrenia are at significantly increased risk of hip fractures compared to the general 
population.  This is concerning since the impact of hip fractures in people with serious mental illness, 
including schizophrenia, is profound and may lead to a worsening mental state (8), higher post-
operative infection rates, worse ambulatory rates after one year, and a risk of contralateral fractures 
(9).   
Recently, several reviews have investigated the influence of antipsychotics on osteoporosis, 
(6, 19, 20) whilst other narrative reviews (5, 7, 21) have considered the prevalence of osteoporosis in 
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schizophrenia. However, to our knowledge, no meta-analysis has assessed the prevalence and 
moderators of low bone mass, osteopenia and osteoporosis in schizophrenia.   
Aims of the study 
In order to determine the degree of low bone mass in people with schizophrenia, we 
conducted a systematic review and meta-analysis with three aims: 1) to investigate the prevalence 
of low bone mass (osteoporosis and osteopenia combined), b) osteopenia and c) osteoporosis in 
people with schizophrenia. 2) To compare the prevalence of low bone mass, osteoporosis and 
osteopenia between people with schizophrenia and age- and sex-matched control subjects. 3) To 
assess if sex, age, smoking status, prolactin-raising antipsychotic use, illness duration, geographical 
region, setting (in- or outpatient) and the assessment method used to quantify low bone mass in 
people with schizophrenia moderated the prevalence of low bone mass, osteoporosis and 
osteopenia. 
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Method 
Inclusion and exclusion criteria 
This systematic review was executed according to Meta-analysis of Observational Studies in 
Epidemiology guidelines (MOOSE) (22) and reported according to the PRISMA statement (23) 
following an a-priori but unpublished protocol. We included observational studies published in any 
language that measured skeletal status or bone mineral density (BMD) and reported prevalence of 
osteoporosis (T-scores of <2.5 or Z-score <2) or osteopenia (T-scores of -1 to -2.5 or Z-score <1) 
according to the World Health Organization criteria (24) in patients with a diagnosis of schizophrenia 
according to the Diagnostic and Statistical Manual (DSM IV;(25)) or International Classification of 
Disease (ICD 10;(26)) criteria.  We also included mixed samples of patients with schizophrenia or 
schizoaffective disorder, but only when >80% had schizophrenia and the corresponding author could 
not provide separate data for schizophrenia patients only.  The primary outcome was the prevalence 
of low bone mass, defined as the combined prevalence of osteoporosis and osteopenia in each 
sample measured with T-score (standard deviation for peak bone mass for sex, 24). If this was not 
available, we used the Z-score (standard deviations from subjects of similar age, gender and 
ethnicity).  We included studies that reported the prevalence of low bone mass with T- or Z-scores 
measured by either dual-energy X-ray absorptiometry (DXA) or quantitative ultrasound (QUS). QUS 
is highly correlated with BMD measured by DXA and is able to predict future fractures (27). In each 
analysis, we pooled the prevalence estimates determined by DXA and QUS together, but conducted 
sensitivity analyses to determine the influence of the method of measurement upon the results. In 
order to reduce heterogeneity, wherever possible we used the T score measured with DXA at the 
lumbar spine since measurements at this site are recommended by international guidelines (4).  
When we identified a study that measured bone mass in patients with schizophrenia, but the 
prevalence was not reported, we contacted the authors up to three times over one month 
requesting the missing information. 
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Studies were excluded that did not: (a) provide prevalence of osteopenia or osteoporosis 
according to a T- or Z-score in line with the WHO-criteria; (b) confirm a diagnosis of schizophrenia 
with DSM-IV or ICD-10 criteria; (c) had insufficient data and/or the authors did not provide sufficient 
information in response to requests for prevalence data. In the case of multiple publications from 
the same study, only the most recent paper or article with the largest sample with complete data 
was included.   
 
Literature search and critical appraisal 
Two authors (BS, DV) independently searched PubMed, Academic Search Premier, 
Psychology and Behavioural Sciences Collection, PsycINFO, EMBASE and CINAHL from inception until 
5th December 2013.  We used the following search terms: (osteoporosis or osteopenia or osteo* or 
bone mineral density or DXA or DEXA or bone) AND (schizophrenia or schizo* or psychosis). Both 
authors independently screened titles and abstracts of all articles, and a list of articles was selected 
by consensus for full text review.  A third reviewer was available for mediation. Subsequently, both 
authors independently reviewed the reference lists of recent systematic reviews on this topic (5-7, 9, 
16, 20, 21). 
All included articles underwent methodological quality assessment by two appraisers with 
the Newcastle Ottawa Scale (NOS). The NOS is a tool used to assess the quality of observational 
studies (28) and its reliability and validity have been established. Scores of 6 or greater are 
considered good methodological quality (28).   
Data extraction 
Two independent authors (BS, DV) extracted information from each study including the 
region the study was conducted, setting (inpatients, outpatient or mixed, i.e. in- and outpatients in 
the same study), socio-demographic information of patients and controls, details of known risk 
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factors for osteoporosis where available (body mass index (BMI), % smokers, type of antipsychotic 
medication, % patients taking prolactin-raising antipsychotics (first-generation antipsychotics and 
amisulpride, paliperidone and risperidone) (16), duration of antipsychotic treatment, duration of 
schizophrenia, percentage of patients with hyperprolactinaemia, serum osteocalcin levels, serum 
vitamin D levels, family/personal history of fractures, and menopausal status for females).   
Data synthesis and analysis 
Due to the anticipated heterogeneity, (22) all analyses were conducted with a random 
effects model using Comprehensive Meta-Analysis Version 2.0. For aim 1, we calculated an 
aggregate event rate (prevalence) for all studies reporting prevalence of low bone mass, osteopenia, 
and osteoporosis in patients with schizophrenia. We calculated the odds ratios (OR) to compare the 
prevalence of low bone mass, osteoporosis and osteopenia between individuals with schizophrenia 
and general population control subjects (Aim 2). 
For aim 3, subgroup analyses were carried out on continuous data examining whether the observed 
variance was significantly explained by continuous variables, such as mean age of the study sample, 
mean BMI, percentage of male participants, percentage of smokers, percentage with 
hyperprolactinemia, percentage of postmenopausal women, and percentage of patients taking 
prolactin-raising antipsychotics. The results of the exploratory moderator analysis were subjected to 
a Bonferroni correction. The global analyses were also subjected to categorical variable data 
analyses to examine the effect of these variables on the existing heterogeneity. We conducted 
numerous subgroup analyses and calculated the prevalence of low bone mass, osteoporosis and 
osteopenia according to geographical area (North America, Asia, Europe and South America), 
prolactin-raising antipsychotic medication (yes, mixed, unclear), method to measure bone mass 
(DXA versus QUS), definition of low bone mass (T-scores and Z-scores) treatment setting 
(outpatients versus inpatients and mixed), and methodological quality (high NOS scores (>6) versus 
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medium and low scores (<5). The MOOSE (22) guidelines recommend that authors conduct subgroup 
analyses to explore possible sources of anticipated heterogeneity.  
To examine the homogeneity of the effect size distribution, the Q-statistic (29) and I2(30) 
were used. When the Q-statistic is rejected, the effect size distribution is not homogeneous, 
implying that the variability in the aggregate prevalence of low bone mass, osteoporosis and 
osteopenia between studies is larger than can be expected based on sampling error alone. To 
examine for publication bias two methods were used concurrently; a) the Begg and Mazumdar's 
rank correlation test (31); and b) the parametric Egger test(32).  All confidence intervals are 
presented at 95%.   
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Results 
Search results, studies and participants 
The initial electronic search yielded 689 valid hits and 19 studies were included in the meta-
analysis (33-51).  At the full text viewing stage, we contacted the authors of 25 publications and of 
these 8 studies were subsequently included (5 authors provided additional data, see 
acknowledgments, and 3 authors did not respond, but contained sufficient data within the paper to 
enable inclusion), and 17 were excluded due to insufficient data.  Full details of the search results 
and reasons for exclusion are summarized in figure 1.  
Figure 1 here 
In total, the dataset included 3,038 schizophrenia patients. The sample size in each study 
ranged from 10 (42) to 965 (48).  The mean age of participants was 42.7 years (range: 24.5 (44) to 
59.1 (37) years) and the mean percentage of males was 59.2%.  Eight studies were conducted in Asia 
(36, 37, 39-41, 47, 48, 50), 7 in Europe (33, 34, 44-46, 49, 51) and 4 in North America (35, 38, 42, 43).  
Eight studies (36, 37, 39-41, 48-50) (n=1,883) were conducted in inpatient settings, 6 included 
outpatients (33, 34, 42, 43, 45, 46) (n=525), 4 studies included participants from mixed settings (35, 
38, 44, 51) (n=545), and the setting was unclear in one study (47) (n=85).  All studies undertook a 
cross-sectional measurement of bone mass. Details on the included studies and the participants are 
presented in table 1. Five studies were considered of high methodological quality scoring 6 and 
above on the NOS (33, 36, 37, 44, 51) and the rest were categorized as being of medium/low quality. 
(see table 1).   
Table 1 here 
There was considerable inconsistency in the reporting of the investigated risk factors for 
osteoporosis. For instance, six studies provided illness duration with an average of 18.4 years (range: 
9.75 (35) to 34.6years (40)), 7 studies provided details about the duration of antipsychotic treatment 
with a mean of 14.2 years (range: 0.2 (44) to 29.6years (40)), ten studies provided details of the 
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percentage of participants taking prolactin-raising antipsychotics (range: 18.6% (35) to 100% (43, 
45)), and 8 studies provided details of the percentage of patients with hyperprolactinaemia (range: 
28% (35) to 84.6% (40)).  Data were available for vitamin D (33) and osteocalcin (35) levels in only 
one study each.  The reporting of lifestyle-related factors also varied; 6 studies reported on the 
prevalence of smoking (range: 29% (36) to 58% (44)), 9 studies reported on BMI; range: 21 (44) to 
30.3 (45)), and 5 studies (40, 41, 45, 46, 49) reported on physical activity through a range of methods 
and subsequent outputs.   
Of the 19 studies, 14 utilized a DXA scanner (33-37, 40-42, 44-47, 49, 51) (n=828 with 
schizophrenia) and 5 studies used QUS (38, 39, 43, 48, 50) (n=2,210 with schizophrenia).   
Only eight studies had a control group, but one (48) was not matched for age and was 
excluded from pooled analysis comparing patients with controls (aim 2).  In total, 7 studies (33, 36, 
37, 42, 44, 50, 51) involving 746 participants with schizophrenia (mean age range: 24.5 (44) to 58.2 
(37) years; percentage of males: 0-100%) and 1,126 age- and sex-matched controls (mean age range: 
23.7 (44) to 59.0 (37) years; percentage of males: 0-100%) were included in the comparative meta-
analysis (aim 2).  Details of the prevalence of low bone mass, osteoporosis and osteopenia from each 
study are summarized in table 1.   
 
Pooled prevalence of low bone mass 
The overall pooled prevalence of low bone mass calculated from 18 studies (33-47, 49-51) 
(n=2,905) was 51.7% (CI=43.05-60.3%; Q=274 (17), p<0.001, I2=93.8%). The Begg-Mazumdar: 
Kendall's tau (-.04, p=0.8) and Egger’s bias tests (-.19, p=0.9) did not demonstrate any evidence of 
publication bias.   
Moderating variables of low bone mass prevalence  
 Lower bone mass prevalence was significantly associated with older age (N=9; n=370; 
p=0.004), higher BMI (N=5; n=189; p=0.018) and a higher percentage of post-menopausal females 
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(N=8; n=305; p=0.016). Conversely, low bone mass was not explained by differences in the 
percentage of male participants (N=12; n=1,096; p=0.38), people taking prolactin-raising 
antipsychotics (N=9; n=826; p=0.44), or people with hyperprolactinemia (N=8; n=400; p=0.46) nor 
the duration of illness (N=4; n=218; p=0.68).  After applying a Bonferroni correction, only age 
remained a significant moderator.   
The prevalence of low bone mass was lower in North America (35.3%, CI=26.6-45.2%, N=4, 
n=835) compared to Europe (53.6%, CI=38.0-68.5%, N=7, n=256) and Asia (58.4%, CI=48.4-67.7%, 
N=7, n=1814).  Studies conducted in inpatient settings had an increased prevalence of low bone 
mass (60.3%, CI=49.6-70.1%, N=7, n=1,750) than those in mixed settings (32.9%, CI=21.6-46.7%, N=4, 
n=545,) and outpatient settings (53.6%, CI=35.6-70.9%, N=6, n=525). A full summary of the 
categorical analyses reporting the prevalence of low bone mass according to geographical region, 
study setting, prolactin-raising medication, type of bone scan, and methodological quality is 
presented in table 2.   
Table 2 here 
Pooled prevalence of osteoporosis  
The overall pooled prevalence of osteoporosis in schizophrenia incorporating 17 studies (33-
42, 45-51 (n=2,671) was 13.2% (CI=7.8-21.6%; Q= 299.79 (16), p=<0.0001, I2=94.6%).  Neither the 
Begg-Mazumdar Kendall's tau (-.117, p=0.5) or the Egger’s bias tests (-1.6, p=0.3) demonstrated any 
evidence of publication bias.   
Moderating variables of osteoporosis  
Osteoporosis was significantly associated with older age (N=8, n=351, p<0.0001), a higher 
percentage of males (N=11, n=957, p<0.0001) and post-menopausal females (N=6, n=242, p=0.01). 
The percentage of the sample with hyperprolactinaemia, the percentage of patients taking prolactin-
raising antipsychotics, the percentage of smokers, duration of illness and BMI were not related to 
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the prevalence of osteoporosis.  After applying the Bonferroni correction, only older age and a 
higher percentage of males remained a significant moderator of osteoporosis in patients with 
schizophrenia.  
The prevalence of osteoporosis was lower in North America 4.75% (CI= 1.50-14.0, N=3, 
n=487) than Europe (15.0%, CI=5.6-34.4, N=6, n=237) and Asia (16.45%, CI=8.12-30.4, N=8, n=1947).  
A higher prevalence of osteoporosis was found in studies that measured BMD with DXA (15.1%, CI: 
9.3-23.7%, N=13, n=809) compared to QUS (10.3%, CI: 2.34-35.9%, N=4, n=1862).  There was a 
higher prevalence of osteoporosis in inpatients settings compared to outpatient settings.  A full 
summary of the subgroup analysis detailing the prevalence of osteoporosis is presented in table 3.   
     Table 3 here 
Pooled prevalence of osteopenia  
The overall pooled prevalence of osteopenia calculated from 17 studies (33-38, 40-42, 44-
51) (n=2,556) was 40.0% (CI=34.7-45.4%; Q=79.8 (16), p<0.0001, I2=79.9%).  Both the Begg-
Mazumdar: Kendall's tau (-.33, p=0.06) and the Egger’s bias tests (-.87, p=0.34) failed to find any 
statistically significant evidence of publication bias.   
Moderating variables of osteopenia  
Osteopenia was significantly associated with a higher percentage of males (N=10, n=824 
p<0.0001) and smokers (N=6, n=173 p=0.01).  BMI, older age, percentage of post-menopausal 
females, illness duration of illness, the percentage with hyperprolactinaemia did not have a 
significant effect on the prevalence of osteopenia.  Only a higher percentage of males remained 
significant in the moderator analysis after applying the Bonferroni correction.   
Studies including participants who all took prolactin-raising antipsychotics had a higher 
prevalence of osteopenia (49.9%, CI=43.8-55.9%, N=4, n=354) compared to studies in which only 
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some patients took prolactin-raising antipsychotics (30.0%, CI= 22.7-38.5%, N=6, n=593). Studies 
reporting osteopenia measured by DXA reported a higher prevalence (40.9%, CI=35.2-46.8%, N=14, 
N=828) than those using QUS (37.9%, CI: 26.5-50.7%, N=3, n=1729). A full summary of the 
prevalence of osteopenia according to the geographical region, study setting, type of bone scan and 
methodological quality is presented in table 4.  
Table 4 here 
Prevalence of low bone density, osteopenia and osteoporosis in patients with schizophrenia 
compared to matched controls 
Patients with schizophrenia (n=746) had a significantly increased risk of low bone mass 
compared to controls (n=1,126, OR=1.9, CI=1.30-2.77, p<0.001). This remained evident when 
analyzing only studies that used DXA scans (n=679, OR=2.28, CI=1.60-3.23, p<0.0001).  The pooled 
risk of osteoporosis was significantly higher in patients with schizophrenia (n=717) vs. controls 
(n=1107) (n=5 studies; OR=2.86, CI=1.27-6.42, p=0.01) and this was also the case when only 
analyzing studies using DXA scores (schizophrenia (n=355) vs. controls (n=275): OR=2.23, CI=1.40-
3.56, p=0.0007). The pooled risk of osteopenia was not significantly increased in patients with 
schizophrenia (n=735) compared to controls (n=1,127) in the pooled analysis involving 6 studies 
(OR=1.33, CI=0.934-1.90, p=0.1). The same was true in the studies using DXA scans (schizophrenia 
(n=373) versus controls (n=492): OR=1.65, CI=0.94-2.90, p=0.07).   
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Discussion 
Key findings 
To the authors’ knowledge, this is the first meta-analysis to investigate the prevalence of low 
bone mass and osteoporosis in patients with schizophrenia. Our meta-analysis indicates that 
patients with schizophrenia are almost twice as likely as age- and sex-matched controls to have low 
bone mass (OR=1.9, CI=1.3-2.7), a condition that affected approximately one in two patients (51%, 
CI= 43%-60%). We also found that approximately one in eight patients with schizophrenia had 
osteoporosis (13.2%, CI=7.8%-21.6%) and patients were over two and a half times more likely to 
have osteoporosis compared to the control populations (OR=2.86, CI=1.27-6.42). The pooled 
prevalence of osteopenia in patients with schizophrenia was 40.0% (CI=34.7%-45.4%) and was not 
statistically different to the comparison group (OR= 1.33, CI=0.93-1.90).   
Our results build upon earlier narrative reviews (52). The findings of increased levels of low 
bone mass and in particular osteoporosis in schizophrenia patients is concerning given the 
consequences of fractures in this population (8, 9, 17, 18). Our systematic review identified only 19 
eligible publications within the period from 2002-December 2013 (33-51) (Figure 1), indicating that 
the issue of bone health has been a low priority until relatively recently.   
 
When considering bone health, identifying patients who currently have, or are at high risk for low 
bone mass is a clinical imperative. Knowledge about factors that are associated with low bone mass 
rates can help identify patients at greater risk. It is well established that people with schizophrenia 
typically have reduced levels of physical activity (13, 14, 53), poor diet (54), inadequate calcium 
intake, reduced levels of vitamin D and high levels of smoking (12) and these all likely contribute to 
the increased risk of low bone mass in schizophrenia. However, due to the paucity and inconsistency 
of the reporting of possible risk factors, the heterogeneity of populations, settings, and assessment 
methods, our moderator analyses did not enable us to clearly elucidate the mechanisms by which 
bone mass is decreased in people with schizophrenia.  Surprisingly, we found inconsistent results in 
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our analyses regarding the influence of prolactin-raising antipsychotics and hyperprolactinemia. 
However, this is highly likely to be due to the heterogeneity and lack of studies providing accurate 
data on these important factors. We found interesting variations in the prevalence of low bone 
mass, with North America (35.3%, CI: 26.6-45.2%) having a particularly lower prevalence compared 
to Europe (53.6%, CI=38.0-68.5%) and Asia (58.4%, CI=48.4-67.7%), but there were no significant 
regional differences in osteoporosis and osteopenia. These geographic differences possibly suggest 
that protective factors, including genetic and environmental (lifestyle) effects, may play a role in 
modifying low bone mass risk in people with schizophrenia. It is established that the introduction of 
vitamin D fortified foods in the US has contributed to improved bone health in the general 
population (55) and this may have contributed to the lower prevalence of low bone mass even in 
high-risk groups, such as schizophrenia patients in the US.  However, there was high heterogeneity in 
most of the subgroup analyses and these results should therefore be interpreted with caution. These 
results point to the fact that currently unmeasured moderator and mediator variables need to be 
assessed in future studies, such as diet and exercise, smoking frequency, cumulative time and dose 
of prolactin-raising and prolactin-neutral antipsychotic treatment, and pre-antipsychotic bone 
density measures.  Moreover, once more studies are available, each providing data on the same and 
expanded set of moderator variables, multivariate regression analyses can be conducted that will 
further enhance the ability to examine the reasons for the heterogeneity of the findings.    
Moreover, it is surprising that a higher BMI appeared to be a significant moderator of low bone mass 
while the converse is true in the general population (2, 4). The exact reasons for this finding are 
unclear, but this association may be attributable to a higher prevalence of unhealthy lifestyle factors 
(in particular sedentary behavior resulting in less bone re-modelling) and increased use of 
antipsychotic medications in individuals with a higher BMI.  However, when applying a Bonferroni 
correction, this finding was not significant anymore.   
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Unsurprisingly, studies conducted in inpatient settings, where patients are likely to be in a more 
acute phase of illness and have restricted activity levels, had an increased prevalence of low bone 
mass compared to those in outpatient settings.  Patients with schizophrenia are already less likely to 
receive adequate care for their reduced bone health (52), and inpatients appear to be most at risk 
for osteoporosis and receiving adequate care. Since we did not have any low bone mass data for 
drug-naïve people with schizophrenia relative to age- and sex-matched comparison subjects, it is not 
clear whether people with schizophrenia have a higher intrinsic vulnerability to low bone mass in the 
absence of medication.   
 
Interestingly, in the exploratory meta-regression analyses, we found that a higher 
percentage of males were significantly associated with a higher prevalence of osteopenia and 
osteoporosis. Previous research demonstrated that risk of hip fracture is particularly elevated in 
male patients with schizophrenia (17) , and others (9) have speculated that this may be due to the 
fact that the onset of mental illness is earlier in males and crucially around a time when peak bone 
mass may not yet have been attained.   
 
Clinical implications 
We recommend that bone health assessments should form an integral part of the 
multidisciplinary treatment of schizophrenia. One clear way to identify those at risk is to measure a 
patient’s skeletal status with QUS or BMD with DXA.  DXA is the gold standard and is required to 
make a definitive diagnosis of osteoporosis, but is often inaccessible and impractical (56, 57). 
Although our results indicated that QUS underreported the prevalence of osteoporosis and 
osteopenia (but not of low bone mass), we believe this should be offered as a practical minimum. 
QUS is comparatively inexpensive, quick, easily transportable and does not emit radiation and 
results are highly correlated to DXA scans (48, 56-59).  In addition, the United States preventative 
taskforce in their recommendation statement state that QUS of the calcaneus is as effective as DXA 
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in predicting future femoral neck, hip and vertebral fractures (60).  Offering QUS assessments is 
particularly pertinent in inpatient settings where we found the highest prevalence of low bone mass, 
but also because it is an environment where access to a DXA scanner at a general hospital is much 
more difficult. However, it is essential that any patient identified as having low bone mass, 
osteoporosis or osteopenia with QUS should subsequently receive a central DXA scan (4) followed by 
appropriate intervention in case any pathological bone density loss is confirmed. In the United 
Kingdom, the National Osteoporosis Society states that individuals in the general population who 
have had a DXA scan should not need another one for at least two years (61).  The European 
osteoporosis management guidelines (4) state that treatment for osteoporosis can be considered 
without a confirmatory DXA scan in environments where patients have limited access to 
densitometry.  Therefore, patients with schizophrenia could possibly be considered for treatment 
under this category, especially if they had had a positive screen for osteoporosis with a QUS scan.  
The American College of Preventative Medicine report that DXA scan screening is cost effective in 
certain high risk populations (e.g. people over 70 years of age) but it remains unclear if this applies 
to people with schizophrenia (62). Currently, specific recommendations for the trigger points for and 
frequency of DXA screening for all people with schizophrenia or high risk subgroups cannot be made 
beyond the available recommendations for the general population. Future research is needed to 
determine if indications for and cost-effectiveness of osteoporosis screening in people with 
schizophrenia differ from the general population. 
 
The prevention and treatment of low bone mass requires a multidisciplinary team approach 
involving psychiatrists, physicians, physical therapists, and other members who should educate and 
help motivate people with schizophrenia to improve their lifestyle. This should include effective 
lifestyle interventions, including smoking cessation, improved diet and exercise (7). Next to these, 
the treating psychiatrist should consider preferential use of or switching to a lower-risk medication 
(e.g. prolactin-sparing antipsychotic; (7)) or adding medication, such as bisphosphonates, selective 
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oestrogen receptor modulators and calcitonin to prevent or treat low bone mass (4, 7). Guidelines 
on the management of osteoporosis in general medicine from the United States (60) and Europe (4) 
recommend that management strategies include the promotion of physical activity. Research has 
consistently established that patients with schizophrenia are inactive (13), and our findings provide 
additional reasons for healthcare professionals to encourage patients to engage in more physical 
activity. Many osteoporotic fractures occur as a result of a falls, and physical activity is also effective 
in reducing the risk of falls (63), thus, providing a further imperative for promoting physical activity 
in patients with schizophrenia. Physical therapists can play a key role in promoting physical activity 
and also in the prevention of falls in this group.   
 
Future research 
Future research should prioritize the use of central DXA scans to measure BMD utilizing 
longitudinal designs.  Future research should also examine whether low bone mass is moderated by 
genetic factors in addition to clinical characteristics. Within general medicine, there has been 
considerable emphasis on the development of lifestyle interventions to prevent osteoporosis.  We 
believe it would be particularly pertinent to investigate the influence of physical activity upon bone 
mass in patients with schizophrenia. In particular, exercise plans should take into account the 
patient’s risk of falls and include measures to reduce this risk.  Future studies should prospectively 
examine the interaction between specific antipsychotics and prolactin levels and bone density, as 
well as the interaction with specific genotypes that could further moderate this risk.   
 
Limitations 
We wish to acknowledge several limitations in the primary data and our meta-analysis. First, 
considerable methodological heterogeneity was found across studies. In accordance with the 
MOOSE guidelines, we stratified the results in various subgroup analyses. Our results indicate that 
the heterogeneity, although expected, can only partly be controlled or explained by stratification for 
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osteoporosis and osteopenia, year of publication, treatment setting, sex, antipsychotic use, type of 
scan, methodological quality of the studies, and lifestyle factors.  Since the heterogeneity often 
remained high in each subgroup analysis, the results should be interpreted with caution.   Second, 
because our study findings were based on cross-sectional rather than longitudinal data, 
directionality of the association between the variables we investigated (including antipsychotic 
medication) and the observed low bone mass cannot be deduced with certainty. Third, a threat to 
the validity of any meta-analysis is publication bias. However, the Begg-Mazumdar and Egger’s bias 
tests did not indicate any evidence of publication bias. Fourth, there was considerable inconsistency 
and heterogeneity in the reporting of risk factors for low bone mass and there were often missing 
data on duration of illness and duration of antipsychotic treatment, limiting the power for 
moderator analyses. In addition the moderator analyses should be considered as exploratory. Fifth, 
there were inadequate data on specific medications making it difficult to determine the influence of 
antipsychotic medications on the observed results. Sixth, only a few studies compared prevalence 
estimates in patients with schizophrenia with matched general population samples of the same 
region. Seventh, lifestyle behaviors were insufficiently recorded, precluding the meta-analytic 
assessment of these factors as moderating or mediating variables. Eighth, we pooled studies using T- 
and Z-scores obtained by DXA and QUS together and the accuracy of combining of DXA and QUS 
quantitative criteria have not been established. In addition, while QUS and DXA are highly correlated 
and QUS is as effective as DXA at predicting future fractures, they do provide different measures of 
bone structure. Finally, only five of the included studies were of high methodological quality. 
However, this is not completely unexpected as most studies did not have a control group and, 
consequently, such studies are expected to receive lower quality scores. Our categorical analyses 
demonstrated that there was no significant effect of study quality on the reported prevalence. 
Nevertheless, to our knowledge, this is the largest study of low bone mass prevalence figures in 
people with schizophrenia and the first formal meta-analysis of this important topic. 
Conclusions 
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Our meta-analysis demonstrates that low bone mass affects more than half of the people 
with schizophrenia. Of greatest concern is the fact that osteoporosis is two and half times more 
common than in controls of a similar age and sex. In recognition of the possible adverse outcomes of 
fractures, multidisciplinary teams should routinely screen for and implement appropriate 
interventions targeting bone health. Future research should focus on evaluating modifiable risk 
factors and interventions that prevent bone mineral loss in people with schizophrenia.  
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Table 1. Summary of included studies 
Study/ 
Reference 
Number 
Design and 
setting 
Schizophrenia 
participants 
N, % male, 
Age and 
population 
details 
Diagnostic 
criteria 
Other details Other details 
(Duration of illness, duration of 
antipsychotic treatment, type of 
antipsychotic, lifestyle factors, 
Controls 
N, % male, 
Age 
NOS 
score 
Type of 
bone 
scan & 
measure
ment 
Number (%) patients 
with schizophrenia 
with low bone mass, 
osteoporosis and 
osteopenia 
Number (%) 
controls with 
schizophrenia with 
low bone mass, 
osteoporosis and 
osteopenia 
33 Serbia 
Cross 
sectional 
Out-
patients 
N=26 
31.3±1.1 years 
12 (50%) male 
All outpatients 
with well-
controlled 
schizophrenia 
without any 
other 
psychiatric 
comorbidity. 
DSM IV BMI 28.2 ±1.0 
Duration of schizophrenia 7.7 ±1.1 
years 
Duration of AP 6.9±1.0 years 
Smokers: 
Schizophrenia 46%, controls 20% 
p=0.02 
Regular menstrual cycles: 
Schizophrenia 86%, controls 92% 
PNSS 76.0±2.9 
All on risperidone 18.0±1.6 
months 
Physical activity 
Serum 25(OH)D nmol/ l: 
Schizophrenia 23.6, controls 71.9 
(p<0.001) 
Osteocalcin ng/ml: 
Schizophrenia 18.0, controls 16.1  
35 health 
controls 
Matched 
age, gender 
and BMI 
 
32.2±1.4 
years 
 
12 males 
6 DXA 
 
Z score 
 
Lx spine 
Low bone mass: 
Total 14 (53.8%) 
 
Osteoporosis: 
Total 3 (11.5%) 
 
Osteopenia:  
Total 11 (42.3%) 
 
Low bone mass: 
Total 10 (28.5%) 
 
Osteoporosis: 
Total 2 (5.7%) 
 
Osteopenia:  
Total 8 (22.8%) 
 
34 UK 
Cross 
sectional 
Out-
patients 
N= 48  
46.6±12.3 
years 
24 (50%) male 
Consecutive 
outpatients 
invited to 
participate in 
the study 
ICD 10 All patients on long term 
antipsychotic medication ? length 
No control 
group 
3 DXA 
 
T score 
 
Lx spine 
Low bone mass: 
Total 32 (66.7%) 
 
Osteoporosis: 
Total 4 (8.3%) 
Osteopenia:  
28 (58.3%) 
 
N/A 
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antipsychotic treatment, type of 
antipsychotic, lifestyle factors, 
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N, % male, 
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score 
Type of 
bone 
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measure
ment 
Number (%) patients 
with schizophrenia 
with low bone mass, 
osteoporosis and 
osteopenia 
Number (%) 
controls with 
schizophrenia with 
low bone mass, 
osteoporosis and 
osteopenia 
35 
 
 
Cross 
sectional 
USA 
Mixed in- 
and out-
patients 
N=75  
34.8±6.2 years 
 
57 males 
(76%) 
 33.6±5.4 
years 
 
18 females  
38.3±7.4 years 
In- and 
outpatients 
invited to take 
part in the 
study.  
 
ICD 10 All receiving AP >1 year 
BMI total sample 27.6±5.4 
Males = 27.5±4.9, females 27.7 
±6.7 
Duration of illness: Total sample 
118.0±83.5 
Male 117.0±77.3 months 
Females 121.2±103.0 months 
PNSS scores total sample 62.2 
±21.3 
Males 61.4±21.2, females 
64.8±21.8 
 
52 (69.3%) smokers 
Non PR AP medication: 
45 (78.9%) males and 13 (72.2%) 
females 
PR AP medication 
10 (17.5%) males and 4 (22.2%) 
females 
 
No control 
group. 
4 DXA  
 
T score 
 
Lx spine 
Low bone mass: 
Total 38 (50.6%) 
 
Osteoporosis: 
Total: 6 (8%) 
 
Osteopenia:  
Total 32 (42.6%) 
 
 
 
 
 
N/A 
36 Cross 
sectional 
Korea 
 
N=51 
30 (58.8%) 
males  
39.9 ±5.1 
years 
 
DSM IV All taken haloperidol for >2 years, 
mean duration of treatment  
Males 89.5 ±59.5 months 
Females 84.5 ±62.2 months 
BMI: 
Males 23.9 ±5.6 
57 healthy 
controls 
40.3±3.3 
years female 
36.9±6.5year
s male 
6 DXA 
 
T score 
 
Lx spine 
Femoral 
Low bone mass: 
Total 33 (64.7%) 
 
Osteoporosis: 
Total 6 (11.8%) 
 
Low bone mass: 
Total 25 (43.8%) 
 
Osteoporosis: 
Total 4 (7%) 
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Number (%) 
controls with 
schizophrenia with 
low bone mass, 
osteoporosis and 
osteopenia 
21 females 
(41.2%) 
37.8 ±5.5 
years 
All patients 
clinically 
stable. 
Females 23.5 ±3.4  
Smokers: 
Males 15 (50%) 0 females 
17 (80.9%) of females had 
amenorrhea  
BMI: 
Males 24.1 
±4.8  
Females 
22.±8 4.9 
Smokers: 
13 (38.2%) 
males and 0 
females 
neck and 
trochante
r 
Osteopenia:  
Total 27 (52.9%) 
 
 
 
 
Osteopenia:  
Total 21 (36.8%) 
 
 
 
37 Cross 
sectional 
Korea 
In-patients 
N=229 
136 (59.4%) 
males  
58.2±5.7 years 
 
93 females 
(40.6%) 
59.1±7.8 years 
 
All clinically 
stable on 
current 
medication 
for 1 year.  
DSM IV All 50 years and older 
100% females postmenopausal 
BMI: 
Males 23.1±3.5 
Females 22.3±3.8  
Duration of illness: 
Males 135.3± 77.9 months 
Females 149.0± 82.0 months 
Smokers total sample: 
88 (38.4%) 
Fracture history total sample: 
55 (24.0%) 
Alcohol dependence diagnosis: 
45 (33.1%) males 
8 (8.6%) 
AP medication  
206 (89.9%) taking first 
generation 
125 healthy 
volunteers 
65 males & 
60 females 
59.0 ±6.8 
years males 
58.2 ± 6.0 
years 
females 
BMI: 
Females 
22.5±2.4 
Males 
21.9±2.8 
Smokers: 
11 (8.8%) 
Fracture 
history: 
6 DXA 
 
T score 
 
Lx spine  
Femur 
neck &  
trochante
r 
Low bone mass: 
Total 183 (79.9%) 
 
Osteoporosis: 
Total 80 (34.9%) 
 
Osteopenia:  
Total 103 (45.0%) 
 
 
Low bone mass: 
Total 83 (66.4%) 
 
Osteoporosis: 
Total 23 (18.4%) 
 
Osteopenia:  
Total 60 (48%) 
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23 (10.0%) taking second 
generation 
 
7 (5.6%) 
38 Cross 
sectional 
USA 
Mixed in- 
and out-
patients 
N=402 
 
255 (63.4%) 
males 40.8 
±10.0 years 
 
147 females 
44.5 ±11.4 
years 
 
Participants 
attended 1 of 
27 centres 
across the 
USA. Post hoc 
analysis of 
large open 
label trial.  
DSM IV 
schizophrenia 
and schizo-
affective 
disorder  
Average AP treatment (all drugs) 
>8±5.8 years 
Menopausal status 51 (34.7%) 
post-menopausal  
Hyperprolactinaemia: 
110 (43%) males 
90 (31%) females  
No control 
group. 
4 QUS 
 
T scores 
Calcaneus 
Low bone mass: 
Total 110 (27.6%) 
 
Osteoporosis: 
Total 8 (1.9%) 
 
Osteopenia:  
Total 102 (25.4%) 
 
 
N/A 
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Cross 
sectional 
Japan 
In-patients 
 
N=133 100% 
female 
55.4±15.9 
years 
All inpatients 
and able to 
DSM-IV 
schizophrenia 
/ schizo-
affective 
disorder 
All had no conditions affecting 
BMD 
No control 
group. 
4 QUS 
 
T score 
 
Calcaneus 
 
Low bone mass: 
N/A 
 
Osteoporosis: 
Total 78 (58.6%) 
 
N/A 
 
Table 1. Summary of included studies 
Study/ 
Reference 
Number 
Design and 
setting 
Schizophrenia 
participants 
N, % male, 
Age and 
population 
details 
Diagnostic 
criteria 
Other details Other details 
(Duration of illness, duration of 
antipsychotic treatment, type of 
antipsychotic, lifestyle factors, 
Controls 
N, % male, 
Age 
NOS 
score 
Type of 
bone 
scan & 
measure
ment 
Number (%) patients 
with schizophrenia 
with low bone mass, 
osteoporosis and 
osteopenia 
Number (%) 
controls with 
schizophrenia with 
low bone mass, 
osteoporosis and 
osteopenia 
perform 
certain level 
of activities of 
daily living. 
Osteopenia:  
N/A 
 
40 Cross 
sectional 
Japan 
In-patients 
N= 74 
100% male 
58.9±12.2 
years 
All 
hospitalised 
and free from 
comorbidities 
that may 
influence 
BMD. 
DSMI IV Durations of illness 34.6±13.0 
years 
Treatment duration 34.6 
years±14.8 years 
37 (50%) smokers 
Physical activity (pedometer steps 
per day, n=63): 
27 (<5,000 steps), 20 (5,000-9,999 
steps) and 16 (10,000 steps). 
87% hyperproaclintainaemic  
 
No control 
group. 
4 DXA 
 
T score 
 
Distal 
radius 
Low bone mass: 
Total 48 (64.8%) 
 
Osteoporosis: 
Total 20 (27%) 
 
Osteopenia:  
Total 28 (37.8%) 
 
N/A 
41 Cross 
sectional  
Taiwan 
In-patients 
N=48, 100% 
female 
24 taking 
prolactin 
raising (PR) 
antipsychotics 
41.8±8 years 
 
24 taking 
clozapine, 
41.7±10.2 
years 
DSM IV PR BMI 25.3±4.1 
Clozapine BMI 25.7±4.1 
Duration of disease: 
PR group 245.5±130 months 
Clozapine 255.6±108.9 months 
Duration hospitalisation: 
PR group 683.3±546.1 months 
Clozapine 944.2±763.9 months 
PANSS total score: 
PR 77.8±17.6 
Clozapine 87.2±19.3 
Physical activity (Pedometer steps 
No control 
group. 
4 DXA 
 
T score 
 
Lx spine  
Low bone mass: 
Total 15 (31.2%) 
 
Osteoporosis: 
Total 1 (2.1%) 
 
Osteopenia:  
Total 14 (29.2%) 
 
N/A 
Table 1. Summary of included studies 
Study/ 
Reference 
Number 
Design and 
setting 
Schizophrenia 
participants 
N, % male, 
Age and 
population 
details 
Diagnostic 
criteria 
Other details Other details 
(Duration of illness, duration of 
antipsychotic treatment, type of 
antipsychotic, lifestyle factors, 
Controls 
N, % male, 
Age 
NOS 
score 
Type of 
bone 
scan & 
measure
ment 
Number (%) patients 
with schizophrenia 
with low bone mass, 
osteoporosis and 
osteopenia 
Number (%) 
controls with 
schizophrenia with 
low bone mass, 
osteoporosis and 
osteopenia 
 
All with 
chronic 
schizophrenia 
and 
hospitalised 
for ≥6 
months. 
per day) 
PR 6593.2±6287 
Clozapine 4944.9±4138.2 
Post-menopausal: 
PR 3 (12.5%) 
Clozapine 4 (16.7%) 
Hyperpractinaemia: 
PR group 23 (95.8%) 
Clozapine 5 (20.8%) 
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Cross 
sectional  
USA 
? setting 
N= 10  
100% male 
48.1±6.5 years 
All with 
chronic 
schizophrenia 
? criteria 
Schizophrenia
/ schizo-
affective 
disorder  
 
100% smokers p=0.037 difference 
to controls  
BMI 30.4 ±6.4 ns difference to 
controls 
10 age and 
gender 
matched 
controls 
100% male, 
had 
treatment 
for 
depression 
and/ or post-
traumatic 
stress 
disorder 
4 DXA 
 
T score 
 
Unclear 
Low bone mass: 
Total 4 (40%) 
 
Osteoporosis: 
Total 1 (10%) 
 
Osteopenia:  
Total 3 (30%) 
 
Low bone mass: 
Total 0 
 
Osteoporosis: 
Total 0 
 
Osteopenia:  
Total 0 
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Cross 
sectional  
Community 
USA 
N= 384  
248 males 
(64.5%) 
All treated in 
? criteria  
Schizophrenia 
All taking conventional PR 
antipsychotics medication or 
atypical risperidone. 
 
N/A 3 QUS 
 
T score 
 
Low bone mass: 
Total 111 (28.9%) 
 
Osteoporosis: 
N/A 
Table 1. Summary of included studies 
Study/ 
Reference 
Number 
Design and 
setting 
Schizophrenia 
participants 
N, % male, 
Age and 
population 
details 
Diagnostic 
criteria 
Other details Other details 
(Duration of illness, duration of 
antipsychotic treatment, type of 
antipsychotic, lifestyle factors, 
Controls 
N, % male, 
Age 
NOS 
score 
Type of 
bone 
scan & 
measure
ment 
Number (%) patients 
with schizophrenia 
with low bone mass, 
osteoporosis and 
osteopenia 
Number (%) 
controls with 
schizophrenia with 
low bone mass, 
osteoporosis and 
osteopenia 
Out-
patients 
the 
community 
for >3 months 
Excluded those taking prolactin 
sparring antipsychotic medication 
(quetiapine, olanzapine, or 
clozapine) 
Calcaneus N/A 
 
Osteopenia:  
N/A 
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Cross 
sectional 
Serbia 
? setting 
 
N=19 
100% female  
24.5±3.8 years 
All females 
recruited as 
soon as 
possible after 
presenting in 
a first 
episode.  
DSM IV 
schizophrenia 
or 
schizophreni-
form disorder  
All first episode psychosis 
Education secondary/ higher 
degree=80%/20% 
11 (57.9%) smokers 
BMI 22.8 
20 healthy 
controls 
100% female 
matched for 
age 23.7±3.1 
years and 
education 
secondary/hi
gher 
degree=84%/
16%, 
(p=0.73) 
BMI 21.0 
6 DXA 
 
Lx spine 
(L1-4) 
Low bone mass: 
Total 4 (21%) 
 
Osteoporosis: 
Total 0 
 
Osteopenia:  
Total 4 (21%) 
 
Low bone mass: 
Total 1 (5%) 
 
Osteoporosis: 
Total 0 
 
Osteopenia:  
Total 1 (5%) 
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Cross 
sectional 
Ireland and 
UK 
Out-
patients 
N= 55 
 
30 male 
(54.5%) 
43.5±11.4 
years 
25 females 
59±5.5 years 
All females 
DSM IV 
Schizophrenia 
All treated on prolactin raising 
antipsychotic medication >10 
years 
BMI: 
28.0 ±4.4 male 
30.3 ±4.6 female 
Treatment duration 
16±7.7 years male group 
21±5.5 years female group  
N/A  4 DXA  
 
Z score 
 
Lx spine  
Left 
femoral 
neck, 
trochante
Low bone mass: 
Total 42 (76.4%) 
 
Osteoporosis: 
Total 11 (20%) 
 
Osteopenia:  
Total 31 (56.4%) 
 
N/A 
Table 1. Summary of included studies 
Study/ 
Reference 
Number 
Design and 
setting 
Schizophrenia 
participants 
N, % male, 
Age and 
population 
details 
Diagnostic 
criteria 
Other details Other details 
(Duration of illness, duration of 
antipsychotic treatment, type of 
antipsychotic, lifestyle factors, 
Controls 
N, % male, 
Age 
NOS 
score 
Type of 
bone 
scan & 
measure
ment 
Number (%) patients 
with schizophrenia 
with low bone mass, 
osteoporosis and 
osteopenia 
Number (%) 
controls with 
schizophrenia with 
low bone mass, 
osteoporosis and 
osteopenia 
post-
menopausal  
46 (83.6%) 
Caucasian 
Recruited 
from 3 sites, 2 
in Ireland and 
1 in UK, all 
treated in the 
community.  
Daily exercise:  
40.3±34.4 min/day Male group  
19.2±15.7 min/ day female group  
BRPS: 
12.2 ±12.7 Male 
12.4 ±17.4 female 
 
ric region  
46 Cross 
sectional 
Ireland 
Out-
patients  
N=38 
100% female 
26 taking 
prolactin 
raising 
antipsychotic 
medication 
32.8 ±6.8 
years 
12 prolactin 
sparring 
medication 
29.5 ±5.7 
years 
All outpatients 
recruited from 
Ireland.  
DSM IV All pre-menopausal women 
receiving antipsychotic 
medication for > 1 year 
PR group: 
BMI 28 ±4.5 
Treatment duration 8.4 ±4.7 years 
Exercise 193.1 ±113 min per week 
SANSS 12.7 ±19.1 
BRPS 5.9 ±5.9 
25 (96%) hyperprolactimaemia 
Prolactin sparring group: 
BMI 27 ±3 
Treatment duration 6.3 ±3.8 years 
Exercise 175.8 ±95.7 min per 
week 
SANSS 12.3 ±17 
BRPS 4 ±6.6 
No control 
group. 
4 DXA 
 
Z score 
 
Lx spine  
Femoral 
neck and 
trochante
ric region 
Low bone mass: 
Total 19 (50%) 
 
Osteoporosis: 
Total 4 (10.5%) 
 
Osteopenia:  
Total 15 (39.5%) 
 
N/A 
 
Table 1. Summary of included studies 
Study/ 
Reference 
Number 
Design and 
setting 
Schizophrenia 
participants 
N, % male, 
Age and 
population 
details 
Diagnostic 
criteria 
Other details Other details 
(Duration of illness, duration of 
antipsychotic treatment, type of 
antipsychotic, lifestyle factors, 
Controls 
N, % male, 
Age 
NOS 
score 
Type of 
bone 
scan & 
measure
ment 
Number (%) patients 
with schizophrenia 
with low bone mass, 
osteoporosis and 
osteopenia 
Number (%) 
controls with 
schizophrenia with 
low bone mass, 
osteoporosis and 
osteopenia 
 4 (33%) hyperprolactinaemia  
47 
 
 
Cross 
sectional 
Iran 
? setting 
 
N=85 
68 (80%) 
males 
39.61± 6.77 
years  
17 females 
(20%) 
36.29± 7.58 
years 
?  N/A No control 
group. 
3 DXA 
 
T score 
 
Lx spine 
Low bone mass: 
Total 46 (54%) 
 
Osteoporosis: 
Total 12 (14.1%) 
 
Osteopenia:  
Total 34 (40%)  
 
 
N/A 
48 Cross 
sectional 
Taiwan 
Inpatients  
N=965 
623 male 
(64.5%) 
47.6±15.9 
years 
 
342 females 
46.81±1.2 
years 
 
All patients 
with chronic 
schizophrenia. 
DSM IV n/a N=405 local 
community  
54.2 ± 16.0 
years 
183 (45%) 
male  
60.0 ± 18.2 
years 
222 (55%) 
female  
Not matched 
on age and 
gender 
4 QUS 
 
T score 
 
Calcaneus 
Low bone mass: 
Total 570 (59.0%) 
 
Osteoporosis: 
Total 129 (13.4%) 
 
Osteopenia:  
Total 441 (45.7%) 
 
 
Low bone mass: 
Total 283 (69.8%) 
 
Osteoporosis: 
Total 71 (17.5%) 
 
Osteopenia:  
Total 212 (52.5%) 
 
 
49 Cross 
sectional 
UK 
N= 21 
71.0 ±10.6 
 
DSM IV On PR AP: 
17 (80.9%) 
History of fractures 7 (33.3%) 
No control 
group. 
3 DXA 
 
T score 
Low bone mass: 
Total 15 (71.4%) 
 
N/A 
 
Table 1. Summary of included studies 
Study/ 
Reference 
Number 
Design and 
setting 
Schizophrenia 
participants 
N, % male, 
Age and 
population 
details 
Diagnostic 
criteria 
Other details Other details 
(Duration of illness, duration of 
antipsychotic treatment, type of 
antipsychotic, lifestyle factors, 
Controls 
N, % male, 
Age 
NOS 
score 
Type of 
bone 
scan & 
measure
ment 
Number (%) patients 
with schizophrenia 
with low bone mass, 
osteoporosis and 
osteopenia 
Number (%) 
controls with 
schizophrenia with 
low bone mass, 
osteoporosis and 
osteopenia 
Inpatients 16 male 
(76.6%) 
 
5 female 
(23.3%) 
 
All long-stay 
inpatients 
with chronic 
schizophrenia.  
 
 
Radius 
Osteoporosis: 
Total 14 (66.67%) 
 
Osteopenia:  
Total 1 (4.7%) 
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Cross 
sectional 
Japan 
Inpatients 
 
N=362 
178 males 
(49.1%) 48.0 ± 
14.9 years 
184 females 
49.7 ± 15.9 
years 
Data collected 
from 3 
hospitals.  
DSM IV 
schizophrenia 
or schizo-
affective 
disorder 
n/a 832 healthy 
volunteers 
 
327 males 
(39.3%) 
56.0 
± 13.8 years 
 
505 females 
58.1 ± 13.0 
years 
4 QUS 
 
T score 
 
Calcaneus 
Low bone mass: 
Total 172 (47.5%) 
 
Osteoporosis: 
Total 13 (3.6%) 
 
Osteopenia:  
Total 159 (43.9%) 
 
 
Low bone mass: 
Total 353 (42.4%) 
 
Osteoporosis: 
Total 1 (0.1%) 
 
Osteopenia:  
Total 352 (42.3%) 
 
51 Cross 
sectional 
Netherland
s and 
Belgium 
N=49 
28.1 years 
39 male 
(79.5%) 
10 female 
DSM IV No demographic information on 
schizophrenia patients.  
N=48 
27.42±6.39 
years 
7 DXA 
 
T SCORE 
 
Lumbar 
Low bone mass: 
Total 15 (30.6%) 
 
Osteoporosis: 
Total 1 (2.0%) 
Low bone mass: 
Total 10 (20.8%) 
 
Osteoporosis: 
Total 1 (2.0%) 
Table 1. Summary of included studies 
Study/ 
Reference 
Number 
Design and 
setting 
Schizophrenia 
participants 
N, % male, 
Age and 
population 
details 
Diagnostic 
criteria 
Other details Other details 
(Duration of illness, duration of 
antipsychotic treatment, type of 
antipsychotic, lifestyle factors, 
Controls 
N, % male, 
Age 
NOS 
score 
Type of 
bone 
scan & 
measure
ment 
Number (%) patients 
with schizophrenia 
with low bone mass, 
osteoporosis and 
osteopenia 
Number (%) 
controls with 
schizophrenia with 
low bone mass, 
osteoporosis and 
osteopenia 
 
Mixed 
setting 
Consecutive 
in- or 
outpatients 
from a larger 
longitudinal 
study 
 
spine  
Osteopenia:  
Total 14 (28.6%) 
 
 
Osteopenia:  
Total 9 (18.75%) 
 
 
Key: NOS = Newcastle Ottawa Scale score, N/A = not available, USA=United States of America, N=Number, PR= prolactin raising, AP=antipsychotic, 
BMI=body mass index, QUS = quantitative ultrasound, DXA= dual-energy X-ray absorptiometry, N/A= not available 
 
Table 2 Pooled and subgroup prevalence of low bone mass in people with schizophrenia  
  N Prevalence 
(95% CI) 
Q-value 
df 
(Q) P-value 
I-
squared 
% 
Overall pooled 
prevalence of low 
bone mass 
 2905 51.7% (43-60) 274.67 17 <0.0001 93.8 
Moderator 
Variable 
Subgroup       
Region  North 
America 
835 35.3% (26.6-
45.2) 
 
15.62 3 0.001 80.8 
 Europe 256 53.6% (38.0-
68.5) 
32.68 6 <0.0001 81.6 
 Asia 1814 58.4% (48.4-
67.7) 
73.27 6 <0.0001 91.8 
Prolactin Raising 
antipsychotic 
medication 
Yes 757 63.1% (40.3-
81.2) 
 
134.0 5 <0.0001 96.2 
 Mixed 593 46.7% (30.0-
64.2) 
49.85 5 <0.0001 89.9 
 Unclear 1555 47.2% (38.6-
55.9) 
33.13 5 <0.0001 84.9 
Type of Bone Scan DXA 828 55.4% (45.1-
65.3) 
 
91.0 13 <0.0001 85.7 
 QUS 2077 41.0% (26.5-
57.2) 
144.7 3 <0.0001 97.9 
Definition of low 
bone mass 
T score 2786 49.5% (39.5-
59.6) 
260.6 13 <0.0001 95.0 
 Z score 119 61.1% (42.4-
77.1) 
7.63 2 0.02 73.8 
Setting of study  Inpatient 1750 60.3% (49.6-
70.1) 
74.0 6 <0.0001 91.89 
 Outpatient 525 53.7% (35.6-
70.9) 
50.02 5 <0.0001 90.0 
 Mixed 630 32.9% (21.6-
46.7) 
16.1 3 0.001 81.43 
Methodological 
quality 
High 374 51.4% (28.0-
74.1) 
55.92 4 <0.0001 92.84 
 Med/ low 2531 51.6% (39.9-
63.0) 
117.47 12 <0.0001 91.9 
Key: N=number of patients with schizophrenia 
